CNE100000NJ9
CNE100000NJ9
LISHENGPHARMA
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 4.39B EUR | 4.38B EUR | 6.1B EUR | 5.59B EUR |
Enterprise Value | 2.19B EUR | 3.14B EUR | 4.65B EUR | 4.1B EUR |
Valuation Multiples | ||||
Trailing P/E | 29.08x | 35.39x | 15.83x | 14.4x |
Forward P/E | -- | -- | -- | -- |
Price to Sales | 3.37x | 4.27x | 5.65x | 5.01x |
Price to Book | 1x | 0.98x | 1.32x | 1.21x |
EV/Revenue | 1.68x | 3.06x | 4.31x | 3.67x |
EV/EBITDA | 11.88x | 23.02x | 10.57x | 9.21x |
Price to FCF (P/FCF) | 12.69x | 89.99x | 36.96x | 34.91x |
EV/FCF | 6.32x | 64.47x | 28.19x | 25.59x |
FCF Yield | 7.88% | 1.11% | 2.71% | 2.86% |